Barinthus Biotherapeutics (NASDAQ:BRNS – Free Report) had its target price cut by HC Wainwright from $5.00 to $3.00 in a research report released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.
Barinthus Biotherapeutics Stock Performance
Shares of BRNS stock opened at $0.94 on Monday. Barinthus Biotherapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $4.16. The stock has a 50 day moving average price of $1.08 and a two-hundred day moving average price of $1.24. The company has a market capitalization of $37.81 million, a P/E ratio of -0.63 and a beta of -0.81.
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.23. The company had revenue of $14.97 million during the quarter. During the same period in the prior year, the firm earned ($0.37) EPS. As a group, equities analysts predict that Barinthus Biotherapeutics will post -1.52 earnings per share for the current year.
About Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
See Also
- Five stocks we like better than Barinthus Biotherapeutics
- The 3 Best Blue-Chip Stocks to Buy Now
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- Comparing and Trading High PE Ratio Stocks
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- How to Evaluate a Stock Before Buying
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
